Balchem Corporation shares reached a 52-week high of $183.90 after exceeding Q3 2026 adjusted EPS forecasts despite a revenue miss. The specialty ingredients firm maintains a Buy rating from H.C. Wain
Balchem Corporation is deemed a high-quality specialty ingredients firm with strong financial health, though analysts warn its current valuation is full relative to market averages. Investors are advi
Balchem Corporation shares trade below intrinsic value following a 47% rally, backed by record sales, a new $650 million credit facility, and share buybacks per DCF analysis.
Balchem Corporation highlights five bakery market trends via a BakeShure infographic, emphasizing healthier consumer preferences and the use of encapsulated active ingredients for product innovation.
Balchem Corporation reported strong third-quarter 2026 sales and net income, supported by a share repurchase boosting EPS. Analysts forecast continued revenue growth through 2029, though capacity and
Balchem Corporation reported strong third-quarter 2026 results, with revenue reaching $290.66 million, an 8.6% increase year-over-year. All three segments showed sales growth driven by market factors
TradingView provides an overview of Balchem Corporation's financials and analyst estimates, including income statements and valuation metrics. Users are advised to conduct independent research as the
Balchem Corporation reported record third-quarter 2026 results with net sales up 8.6% to $290.7 million and adjusted EPS of $1.57, supported by growth across Human Nutrition, Animal Nutrition, and Spe
Balchem Corporation reported Q3 2026 financial results that met Wall Street expectations, with revenue rising 8.6% year-over-year to $290.7 million, driven by growth in its Human Nutrition and Health
A financial data platform provides analyst estimates and historical performance metrics for Balchem Corp (BCPC) listed on the Mexican Stock Exchange. Users can compare actual results against forecasts
Balchem Corporation reported an 8.6% year-over-year increase in third-quarter net sales to $290.7 million, driven by growth across its Human Nutrition, Animal Nutrition, and Specialty Products segment
Balchem Corporation reported record Q3 2026 net sales of $270.8 million, a 16.7% increase year-over-year, driven by strong performance in nutrition segments and acquisitions.
Balchem Corporation reported record third-quarter 2026 financial results, with net sales increasing 8.6% year-over-year to $290.7 million. GAAP net earnings rose 16.0% to $46.7 million, supported by g
Financial data from ICE Data Services reports Balchem Corp's pretax income on the Hannover Stock Exchange. The company trades under ticker BL9B, though the market is currently closed with no active tr
Balchem Corp (HAN:BL9B) financial data regarding total non-operating income is presented on the Hannover Stock Exchange, sourced from ICE Data Services and FactSet.
Balchem Corporation reported a minority interest of MXN0.00 million as of June 2026, with a GF Score of 93/100 and two identified investor warning signs.
Balchem Corporation reported current deferred revenue of MXN0.00 million as of June 2026. The article provides historical data and definitions regarding this financial metric sourced from GuruFocus.
Balchem Corporation will showcase its branded ingredients and scientific leadership at SupplySide Global 2026, highlighting new research on health-focused compounds and GLP-1 companion products for fo
Balchem published a whitepaper exploring DNA methylation's role in cellular health throughout life. The paper identifies nutrient gaps and highlights the growing market for methyl-donating ingredients
Balchem Corp disclosed its cash flow from investing activities on the Hannover Stock Exchange. Market data indicates the trading platform currently shows no active trades.
Balchem Corp (HAN:BL9B) operating cash flow data is listed on the Hannover Stock Exchange, where the market is currently closed with no trades recorded. Data is supplied by ICE Data Services and FactS
Balchem Corporation reported total revenue of 883.06 million EUR last year, with its Human Nutrition and Health segment leading performance. The United States served as the primary regional market, co
Balchem Corporation disclosed net income before discontinued operations, tracked under the Hannover Stock Exchange symbol BL9B. The report details financial metrics including value and change over spe
Balchem Corporation's SVP and Chief R&D Officer Ren Anthony Gonzalez disclosed share holdings, revealing that most direct shares are restricted stock vesting over one to three years.
A Discounted Cash Flow analysis indicates Balchem Corporation is undervalued by roughly 25%, supported by $177.6 million in trailing twelve-month free cash flow. Capacity expansion offers upside, thou
Balchem Corp reported 18.70 billion MXN in annual revenue, with its Human Nutrition and Health segment contributing the majority at 11.89 billion MXN. The United States was the top regional market, ge
Balchem Corporation outlines strategies for manufacturers to meet rising protein demand in meat snacks, noting opportunities from GLP-1 trends and the use of MeatShure® microencapsulated acids.
H.C. Wainwright raised Balchem's price target to $215 following Q2 2026 results that exceeded revenue and earnings estimates, citing consistent growth and 16 consecutive years of dividend increases.
Balchem Corporation reported record quarterly revenue and adjusted EBITDA, yet its stock gained only 3% despite strong profitability trends. Analysts note the high 34.1x P/E ratio requires further eva
Balchem Corporation reported $1.04 billion USD in annual revenue, led by its Human Nutrition and Health segment. The United States contributed the majority of sales, totaling $759.45 million.
Various ETFs, including those from BlackRock and Vanguard, hold Balchem Corporation stock, primarily focusing on small-cap and extended market segments. The data includes financial metrics such as ass
Balchem Corp (BCPC) ranks 6th among 65 Chemicals companies with a financial score of 9.04, posting $270.71 million in quarterly revenue and an 8.72% year-over-year profit increase.
Balchem Corp shares traded near $162 with a slight decline, though analysts maintain a Buy rating with a target price of $200.75. The company is valued fairly within the Chemicals industry, supported
Balchem Corp ranks 28th in the Chemicals industry with a 7.00 institutional confidence score; institutional shareholding fell 4.74% QoQ to 88.34%, while top shareholder ETHSX increased its stake to 2.
Balchem Corp reported 822.23M CHF annual revenue, driven by its Human Nutrition and Health segment (522.74M CHF). The U.S. was the top geographic market, contributing 602.07M CHF.
Balchem Corporation published a detailed cash flow statement covering quarterly and annual periods, including operating, investing, and financing metrics. The report features an FAQ section explaining
Analysts project Balchem Corp (BCPC) to rank 33rd in the Chemicals industry with a $191.00 price target. Next-quarter revenue is expected at $268.50M with an EPS of $1.40.
Balchem Corporation amended its credit facility with JPMorgan, increasing revolving commitments to $650 million and extending maturity to 2031. The changes aim to improve liquidity and lower borrowing
TradingKey provides historical income statement data for Balchem Corp (BCPC) from FY2012Q1 through FY2026Q1, including revenue, expenses, and earnings per share metrics.
Balchem Corp shares rose 1.81% amid positive analyst sentiment, with reports citing strong fundamentals and high growth potential within the Chemicals industry. Analysts recommend a 'Buy' with a targe
Balchem Corporation generated 18.70 billion Mexican Pesos in total revenue last year, driven primarily by its Human Nutrition and Health segment. The United States remained the largest regional contri
The Vitamin K2 market is projected to reach USD 339.9 million by 2031, driven by demand for bone and cardiovascular health solutions. Key players include Gnosis by Lesaffre, Balchem Corp., and Novones
Balchem Corp ranks 62nd out of 65 in the Chemicals industry with a valuation score of 6.27 and a P/E ratio of 33.10, while other financial ratios remain undisclosed.
Argus Research has lowered its price target for Balchem Corporation (BCPC) to $148.00. The company develops and markets specialty performance ingredients for various industries.
Balchem Corporation missed Q3 2024 EPS and revenue expectations despite 4.35% year-over-year revenue growth, reporting actual EPS of $18.03 against consensus of $19.52.
Balchem renewed its partnership with Oregon State University's Linus Pauling Institute to advance education on iron nutrition and epigenetic health. The collaboration promotes Balchem's branded ingred
Balchem Corp (BX:BL9B) displays enterprise value to EBIT forward metrics on the BX Swiss exchange. Trading was closed at publication with no recorded trades.
Balchem Corporation renewed its partnership with Oregon State University's Linus Pauling Institute to expand education on iron nutrition and epigenetic health. The collaboration will enhance the Micro
Analysts forecast Balchem Corp (BL9B) stock prices ranging from 139.72 EUR to 199.35 EUR by 2027, citing recent earnings and revenue performance ahead of the July 24, 2026 report.
Balchem Corporation will release its second-quarter 2026 financial results before market open on July 31, accompanied by a live conference call at 11:00 AM ET for investors and analysts.
ChemBrief